Bambusa Therapeutics, Inc.

BBTX
16.40 0.67 +4.26%
Market cap
$782.8M
P/E
—
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
—
Net debt / EBITDA
—
Dividend safety
n/a

Insider Decisions last twelve months

Net bought
$58.6M
Trades
0 sells · 3 buys
Ownership
—

Capital & Financial Ratios $m

Size
Market Cap 783
Revenue ttm —
Net income ttm —
Free cash flow ttm —
Net debt Q —
Valuation
P/E —
Forward P/E —
Price / sales —
Forward P/S Powerpack
Price / FCF —
Price / book —
Financial health
Current ratio Q —
Debt / equity Q —
Interest coverage Q —
Growth
Revenue growth Q —
Operating income growth Q —
EPS, this year —
EPS, next year A —
Revenue, next year A —
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates; n/m is not meaningful, as a P/E on a loss. How we judge →

Valuation vs history

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 2026
Cash — — — —
Receivables — — — —
Inventory — — — —
Other — — — —
— — — —
2023 2024 2025 2026
Payables — — — —
ST’ Debt — — — —
Other — — — —
— — — —

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow — — —
Earnings — — —
Book Value — — —

EPS $

Year
Fiscal quarters ending in the months shown.

Revenue $m

Year
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Year
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Year
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1Buy 2 3Hold 4 5Sell

Ten years at a glance

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — — — — — — — — — — — —
Gross margin, % — — — — — — — — — — —
EBT — — — — — — — — — — —
EBT margin, % — — — — — — — — — — —
Net income — — — — — — — — — 0 —
Per share, $
Per share, $ Revenue — — — — — — — — — — —
Earnings — — — — — — — — — — —
Cash flow — — — — — — — — — — —
Capex — — — — — — — — — — —
Free cash flow — — — — — — — — — — —
Book value — — — — — — — — — — —
Shares, m — — — — — — — — — — —
Valuation, ×
Valuation, × P/E — — — — — — — — — — —
P/S — — — — — — — — — — —
P/B — — — — — — — — — — —
EV/Sales — — — — — — — — — — —
EV/FCF — — — — — — — — — — —
Cash, $m
Cash, $m Operating cash flow — — — — — — — — — — —
Capex — — — — — — — — — — —
Free cash flow — — — — — — — — — — —
Balance, $m
Balance, $m Working capital — — — — — — — — — — —
Net debt — — — — — — — — — — —
Shareholders’ equity — — — — — — — — — — —
Returns, %
Returns, % ROA — — — — — — — — — — —
ROIC — — — — — — — — — — —
ROE — — — — — — — — — — —
People
People Employees — — — — — — — — — 30 —
Revenue/emp, $m — — — — — — — — — 0.00 —
Negative figures in brackets.
estimates

All 10 years →

Fundamentals updated 5 Nov 2026

Bambusa Therapeutics, Inc. vs peers (Q) = latest quarter vs a year earlier

No peers yet.

Bambusa Therapeutics, Inc. (BBTX) Latest News

stockrow.com/BBTX · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com